Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial
December 11, 2014 at 06:32 AM EST
Vical Incorporated (Nasdaq: VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin^®-formulated ...